ORMP
Oramed Pharmaceuticals Inc. [ORMP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ORMP Stock Summary
Top ORMP Correlated Resources
ORMP
Top 10 Correlated ETFs
ORMP
Top 10 Correlated Stocks
ORMP
In the News
Best Penny Stocks To Buy Today? 4 To Watch Under $5
Penny stocks under $5 to watch this week. The post Best Penny Stocks To Buy Today?
Why Oramed Pharmaceuticals Stock Is Crashing Today
The company's lead pipeline candidate is still being evaluated as a potential treatment for NASH after a major flop in treating type 2 diabetes.
Why Is Oramed (ORMP) Stock Down 75% Today?
Oramed (NASDAQ: ORMP ) stock is falling hard on Thursday after releasing data from a Phase 3 clinical trial. This clinical trial saw Oramed testing the efficiency of ORMD-0801 in patients with Type 2 Diabetes at 26 weeks against those taking a placebo.
Oramed's oral insulin pill fails; stock is down 72%
Shares of Oramed Pharmaceuticals Inc. ORMP, +5.78% plunged 72% in premarket trading on Thursday, the day after the company told investors its oral insulin medication did not meet the primary or secondary endpoints in a Phase 3 clinical trial. The randomized, double-blind, placebo-controlled trial compared Oramed's treatment to placebo to see if it improved glycemic control in patients with type 2 diabetes.
Oramed: NASH Biotech Play With Added Bonus
Oramed achieved positive results from phase 2 study using ORMD-0801 for Type 2 Diabetes patients with NASH. Primary safety endpoint and secondary exploratory biomarker endpoints established proof of concept. Results from the phase 3 study using ORMD-0801 for the treatment of patients with Type 2 Diabetes are expected in January of 2023.
Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Results from Oramed Pharmaceuticals's first phase 3 study ORA-D-013-1, using ORMD-0801 for the treatment of patients with Type 2 Diabetes, is expected January 2023. Results from the ongoing Cohorts A and B, using Oravax for Covid-19, are going to be read out Q3 and Q4 of 2022 respectively.
Why Oramed Pharmaceuticals Stock Is On Fire Today
The biotech's stock has been ripping higher of late.
Why Oramed Pharmaceuticals Stock Rocketed Higher Today
A reassuring letter to shareholders has the biotech's stock jumping today.
Oramed And Oral Insulin: Can This Small Company Really Do It?
Oramed is developing oral insulin in a phase 3 trial, data this year. Nobody has been able to deliver insulin orally in adequate quantity.
Oramed's Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh
Oramed Pharmaceuticals Inc. ORMP, -11.40% said Wednesday its Oravax Medical subsidiary has signed an agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Co. to pre-purchase 10 million doses of Oravax's oral COVID-19 vaccines in development. The drug maker's stock slipped 0.1% in premarket trading.
ORMP Financial details
ORMP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-08-31 | 2019-08-31 | 2020-08-31 | 2021-08-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.16 | 0.15 | 0.13 | 0.09 | 0.07 | |
| Net income per share | -0.8 | -0.82 | -0.57 | -0.71 | -0.97 | |
| Operating cash flow per share | -0.98 | -0.74 | -0.61 | -0.74 | -0.72 | |
| Free cash flow per share | -0.99 | -0.74 | -0.61 | -0.76 | -0.73 | |
| Cash per share | 2.05 | 1.85 | 1.94 | 3.31 | 3.99 | |
| Book value per share | 2.09 | 1.11 | 1.6 | 4.07 | 3.89 | |
| Tangible book value per share | 2.09 | 1.11 | 1.6 | 4.09 | 3.88 | |
| Share holders equity per share | 2.09 | 1.11 | 1.6 | 4.07 | 3.89 | |
| Interest debt per share | 0 | -0.01 | 0 | 0.02 | -0.05 | |
| Market cap | 73.67M | 57.95M | 71.66M | 560.27M | 469.14M | |
| Enterprise value | 68.67M | 54.62M | 52.44M | 483.56M | 429.57M | |
| P/E ratio | -6.18 | -4.04 | -6.12 | -27.86 | -12.42 | |
| Price to sales ratio | 30.08 | 21.44 | 26.44 | 207.28 | 173.56 | |
| POCF ratio | -5.03 | -4.48 | -5.76 | -26.45 | -16.8 | |
| PFCF ratio | -5.02 | -4.47 | -5.72 | -25.99 | -16.51 | |
| P/B Ratio | 2.37 | 2.99 | 2.18 | 4.84 | 3.09 | |
| PTB ratio | 2.37 | 2.99 | 2.18 | 4.84 | 3.09 | |
| EV to sales | 28.04 | 20.21 | 19.35 | 178.9 | 158.92 | |
| Enterprise value over EBITDA | -5.4 | -3.85 | -4.64 | -19.31 | -11.62 | |
| EV to operating cash flow | -4.69 | -4.22 | -4.22 | -22.83 | -15.39 | |
| EV to free cash flow | -4.68 | -4.22 | -4.19 | -22.43 | -15.12 | |
| Earnings yield | -0.16 | -0.25 | -0.16 | -0.04 | -0.08 | |
| Free cash flow yield | -0.2 | -0.22 | -0.17 | -0.04 | -0.06 | |
| Debt to equity | 0.52 | 0.79 | 0.36 | 0.1 | 0.07 | |
| Debt to assets | 0.34 | 0.44 | 0.26 | 0.09 | 0.06 | |
| Net debt to EBITDA | 0.39 | 0.23 | 1.7 | 3.06 | 1.07 | |
| Current ratio | 6.82 | 6.28 | 8.93 | 14.27 | 27.34 | |
| Interest coverage | 0 | 116.12 | 0 | 0 | 13.84 | |
| Income quality | 1.15 | 0.9 | 1.08 | 0.92 | 0.74 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.67 | 1.38 | 1.56 | 2.2 | 5.11 | |
| Research and developement to revenue | 4.89 | 5 | 3.78 | 7.77 | 10.23 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.01 | 0.02 | 0.02 | |
| Capex to revenue | 0 | -0.01 | -0.03 | -0.14 | -0.18 | |
| Capex to depreciation | -0.83 | -1.88 | -11.71 | -4.87 | -8.55 | |
| Stock based compensation to revenue | 0.63 | 0.3 | 0.43 | 1 | 4.26 | |
| Graham number | 6.14 | 4.53 | 4.53 | 8.04 | 9.21 | |
| ROIC | -0.35 | -0.56 | -2.19 | 0.73 | -0.52 | |
| Return on tangible assets | -0.25 | -0.41 | -0.26 | -0.16 | -0.23 | |
| Graham Net | 0.95 | 0.97 | 1.37 | 2.9 | 3.72 | |
| Working capital | 26.48M | 28.02M | 35.98M | 88.66M | 151.36M | |
| Tangible asset value | 31.11M | 19.39M | 32.88M | 116.52M | 151.16M | |
| Net current asset value | 14.75M | 18.05M | 28.76M | 83.86M | 146.62M | |
| Invested capital | 0 | 0 | 0 | 0 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 853K | 1.24M | 965.5K | 1.6M | 2.39M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 4.82K | 5.42K | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.08 | 0.07 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.38 | -0.74 | -0.36 | -0.17 | -0.25 | |
| Capex per share | 0 | 0 | 0 | -0.01 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Net income per share | -0.27 | -0.27 | -0.19 | -0.22 | -0.04 | |
| Operating cash flow per share | -0.24 | -0.22 | -0.06 | -0.21 | -0.14 | |
| Free cash flow per share | -0.24 | -0.22 | -0.06 | -0.21 | -0.14 | |
| Cash per share | 3.66 | 3.45 | 4.08 | 3.99 | 3.84 | |
| Book value per share | 4.2 | 3.96 | 3.93 | 3.89 | 3.77 | |
| Tangible book value per share | 4.19 | 3.94 | 3.92 | 3.88 | 3.75 | |
| Share holders equity per share | 4.2 | 3.96 | 3.93 | 3.89 | 3.77 | |
| Interest debt per share | 0.04 | 0.03 | 0.05 | 0.06 | -0.02 | |
| Market cap | 334.58M | 177.68M | 253.37M | 469.14M | 87.29M | |
| Enterprise value | 307.72M | 148.77M | 221.07M | 429.57M | 63.99M | |
| P/E ratio | -8.02 | -4.22 | -8.73 | -13.73 | -12.14 | |
| Price to sales ratio | 502.37 | 263.62 | 371.51 | 688.9 | 131.07 | |
| POCF ratio | -36.67 | -20.93 | -113.06 | -58.19 | -15.73 | |
| PFCF ratio | -36.48 | -20.88 | -107.27 | -56.05 | -15.19 | |
| P/B Ratio | 2.06 | 1.16 | 1.65 | 3.09 | 0.58 | |
| PTB ratio | 2.06 | 1.16 | 1.65 | 3.09 | 0.58 | |
| EV to sales | 462.04 | 220.72 | 324.15 | 630.8 | 96.08 | |
| Enterprise value over EBITDA | -27.37 | -13.05 | -27.05 | -63.27 | -12.38 | |
| EV to operating cash flow | -33.72 | -17.52 | -98.65 | -53.28 | -11.53 | |
| EV to free cash flow | -33.55 | -17.48 | -93.6 | -51.32 | -11.13 | |
| Earnings yield | -0.03 | -0.06 | -0.03 | -0.02 | -0.02 | |
| Free cash flow yield | -0.03 | -0.05 | -0.01 | -0.02 | -0.07 | |
| Debt to equity | 0.06 | 0.06 | 0.07 | 0.07 | 0.06 | |
| Debt to assets | 0.06 | 0.06 | 0.07 | 0.06 | 0.06 | |
| Net debt to EBITDA | 2.39 | 2.54 | 3.95 | 5.83 | 4.51 | |
| Current ratio | 22.7 | 21.01 | 24.55 | 27.34 | 31.21 | |
| Interest coverage | -20.68 | -32.62 | -7.9 | -5.96 | 3.26 | |
| Income quality | 0.85 | 0.77 | 0.31 | 0.92 | 1.54 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 8.25 | 3.76 | 4.49 | 4 | 1.9 | |
| Research and developement to revenue | 8.76 | 13.62 | 7.84 | 10.69 | 6.65 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0 | 0.05 | 0.04 | 0.04 | |
| Capex to revenue | -0.07 | -0.03 | -0.18 | -0.45 | -0.3 | |
| Capex to depreciation | -4.27 | -1.33 | -8.07 | -18.12 | -5.38 | |
| Stock based compensation to revenue | 6.05 | 2.79 | 4.47 | 3.74 | 0.26 | |
| Graham number | 5.05 | 4.92 | 4.05 | 4.38 | 1.95 | |
| ROIC | -0.1 | -0.11 | -0.09 | -0.12 | -0.02 | |
| Return on tangible assets | -0.06 | -0.06 | -0.04 | -0.05 | -0.01 | |
| Graham Net | 3.4 | 3.21 | 3.79 | 3.72 | 3.6 | |
| Working capital | 137.24M | 128.45M | 153.65M | 151.36M | 150.19M | |
| Tangible asset value | 162.22M | 153.04M | 153.15M | 151.16M | 150.15M | |
| Net current asset value | 133.56M | 125.62M | 148.88M | 146.62M | 145.53M | |
| Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 4.04M | 3.4M | 3.84M | 3.19M | 3.12M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.06 | -0.07 | -0.05 | -0.06 | -0.01 | |
| Capex per share | 0 | 0 | 0 | -0.01 | 0 |
ORMP Frequently Asked Questions
What is Oramed Pharmaceuticals Inc. stock symbol ?
Oramed Pharmaceuticals Inc. is a US stock , located in New york of Ny and trading under the symbol ORMP
What is Oramed Pharmaceuticals Inc. stock quote today ?
Oramed Pharmaceuticals Inc. stock price is $4.075 today.
Is Oramed Pharmaceuticals Inc. stock public?
Yes, Oramed Pharmaceuticals Inc. is a publicly traded company.
Company Profile
- Volume Average 967.31K
- Market Capitalization 160.91M
- Employee 13
- CEO Mr. Nadav Kidron Esq.
- Headquarters New York,NY,US
- IPO Date 2002-04-01
-
Website
https://www.oramed.com 
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
